PEG-IFNα-2a和PEG-IFNα-2b治疗乙型肝炎e抗原阳性乙型肝炎的临

StephenW

PEG-IFNα-2a和PEG-IFNα-2b治疗乙型肝炎e抗原阳性乙型肝炎的临床疗效及其改善患者炎症因子和血流动力学的价值：比较研究
贾妮娜 1 , 伟高 1 , 范晓红 1 , 高红 1 , 李雪清 1 , 卞桃 1 , 杨洁 1
隶属关系
联系

    1
    山西医科大学第二医院消化内科，山西太原 030001

    PMID：35726331 PMCID：PMC9206564 DOI：10.1155/2022/3185320

抽象的

目的：比较PEG-IFNα-2a和PEG-IFNα-2b治疗乙型肝炎e抗原（HBeAg）阳性慢性乙型肝炎（CHB）的优缺点。

方法：回顾性分析山西医科大学第二医院2018年1月至2019年1月收治的84例慢性乙型肝炎患者的临床资料，分为两组：2a组采用PEG-IFNα-2a治疗，2b组采用PEG-IFNα-2a治疗。干扰素α-2b。比较上述两组的临床疗效，肝功能（ALT、AST、HA、LN、IV-C）、HBV-DNA、HBsAg、HBeAg、炎症因子（IFs、IL-1β、IL- 6、IL-8 和 TNF-α) 在 12 周 (T1)、24 周 (T2) 和 48 周 (T3) 进行了测试。记录治疗期间血流动力学（SBP、DBP、MAP和CVP）、心功能（LVEF和BNP）以及不良反应（ARs）发生率的变化。最后对患者进行为期2年的随访，调查患者的生活质量（QOL）以及HBsAg和HBeAg的阳性血清转换率。

结果：两组的总体反应率相似（P > 0.05）。治疗后肝功能、HBV-DNA、HBsAg、HBeAg、IFs、血流动力学、心功能均有明显改善（P < 0.05），2b组较2a组改善更快（P < 0.05）。对 AR 的调查发现，与 2b 组相比，2a 组的脱发、血小板减少症和粒细胞减少症的发生率显着降低（P < 0.05）。预后随访结果显示，生活质量评分和HBsAg、HBeAg阳性血清转化率无明显差异（P>0.05）；但2b组HBV-DNA、HBsAg、HBeAg定量结果低于2a组（P < 0.05）。

结论：PEG-IFNα-2a和PEG-IFNα-2b均对HBeAg阳性CHB具有良好且稳定的治疗效果，其中PEG-IFNα-2b治疗过程更快但副作用更大，可为选择提供有价值的参考。 CHB 的治疗计划。

版权所有 © 2022 Nina Jia 等。

StephenW

Clinical Efficacy of PEG-IFN α-2a and PEG-IFN α-2b in the Treatment of Hepatitis B e Antigen-Positive Hepatitis B and Their Value in Improving Inflammatory Factors and Hemodynamics in Patients: A Comparative Study
Nina Jia  1 , Wei Gao  1 , Xiaohong Fan  1 , Hong Gao  1 , Xueqing Li  1 , Biantao Mi  1 , Jie Yang  1
Affiliations
Affiliation

    1
    Department of Gastroenterology, The Second Hospital of Shanxi Medical University, Taiyuan, 030001 Shanxi, China.

    PMID: 35726331 PMCID: PMC9206564 DOI: 10.1155/2022/3185320

Abstract

Objective: To compare the merits and demerits of PEG-IFNα-2a and PEG-IFNα-2b for the treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB).

Methods: Clinical files from eighty-four CHB patients admitted to the Second Hospital of Shanxi Medical University between January 2018 and January 2019 were retrospectively analyzed and assigned to two groups: group 2a treated with PEG-IFNα-2a and group 2b treated with PEG-IFNα-2b. The clinical efficacy was compared between the above two arms, and the liver function (ALT, AST, HA, LN, and IV-C), HBV-DNA, HBsAg, HBeAg, and inflammatory factors (IFs, IL-1β, IL-6, IL-8, and TNF-α) were tested at 12 weeks (T1), 24 weeks (T2), and 48 weeks (T3). The alterations of hemodynamics (SBP, DBP, MAP, and CVP), cardiac function (LVEF and BNP), and the incidence of adverse reactions (ARs) during treatment were recorded. Finally, the patients were followed up for 2 years to investigate the quality of life (QOL) as well as the positive seroconversion rate of HBsAg and HBeAg.

Results: The overall response rate was similar in the two arms (P > 0.05). After treatment, the liver function, HBV-DNA, HBsAg, HBeAg, IFs, hemodynamics, and cardiac function were enormously improved (P < 0.05), with faster improvement in group 2b compared with group 2a (P < 0.05). The investigation of ARs identified notably lower incidence rates of alopecia, thrombocytopenia, and granulocytopenia in group 2a as compared to group 2b (P < 0.05). The prognostic follow-up results revealed no distinct difference in the QOL score and the positive seroconversion rate of HBsAg and HBeAg (P > 0.05); however, the quantitative results of HBV-DNA, HBsAg, and HBeAg in group 2b were lower than those in group 2a (P < 0.05).

Conclusions: Both PEG-IFNα-2a and PEG-IFNα-2b have excellent and stable therapeutic effects on HBeAg-positive CHB, among which PEG-IFNα-2b renders a faster treatment process but higher side effects, which can provide valuable references when choosing a treatment plan for CHB.

Copyright © 2022 Nina Jia et al.